Publication | Closed Access

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Breast OncologyMedicinePharmacologyNeoadjuvant TreatmentBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyEr-positive Breast Cancer